Who are Coherus Oncology, Inc.'s main suppliers?

Coherus Oncology, Inc. (CHRS) key suppliers include: JUNSHI-BIOSCIENCES, Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., AstraZeneca PLC, AstraZeneca PLC and 15 more. View the full supplier network at chainsifter.com/chain/CHRS.

Who are Coherus Oncology, Inc.'s major customers?

Coherus Oncology, Inc. (CHRS) key customers include: Cardinal Health, Inc., Cardinal Health, Inc., McKesson Corporation, McKesson Corporation, APOTEX and 25 more. View the full customer network at chainsifter.com/chain/CHRS.

What sector is Coherus Oncology, Inc. in?

Coherus Oncology, Inc. (CHRS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Coherus Oncology, Inc. Suppliers, Customers & Supply Chain (CHRS)

20Suppliers

30Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Coherus Oncology, Inc. (CHRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

59Total relationships

4Distinct source URLs

9High confidence

0.724Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Coherus Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
JUNSHI-BIOSCIENCES	JUNSHI-BIOSCIENCES	92%	We are obligated to pay Junshi Biosciences a royalty in the low twenty percent range on net sales of LOQTORZI and up to an aggregate $380.0 million in one-time payments for the achievement of various…
AMRX	Amneal Pharmaceuticals, Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
AMRX	Amneal Pharmaceuticals, Inc.	72%	Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
AZN	AstraZeneca PLC	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMY	Bristol-Myers Squibb Company	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMYM…
BMYMP	Bristol-Myers Squibb Co	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
CAH	Cardinal Health, Inc.	72%	Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from CAH grap…
FMS	Fresenius Medical Care AG	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
FMS	Fresenius Medical Care AG	72%	Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from FMS grap…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
GILD	Gilead Sciences, Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
MCK	McKesson Corporation	72%	Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK grap…
MRK	Merck & Co., Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (v…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN g…
REGN	Regeneron Pharmaceuticals, Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
KLTO	Klotho Neurosciences Inc	62%	Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO g…

Coherus Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
CAH	Cardinal Health, Inc.	95%	e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $ million in c…
CAH	Cardinal Health, Inc.	95%	Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from CAH grap…
MCK	McKesson Corporation	95%	Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: revenue was generated in the United S…
MCK	McKesson Corporation	95%	revenue was generated in the United States. The Company’s net revenue was as follows: Year Ended December 31, (in thousands) 2025 2024 LOQTORZI $ 40,836 $ …
APOTEX	APOTEX	90%	we granted to Apotex an exclusive license under our rights to toripalimab to commercialize toripalimab within Canada
AMRX	Amneal Pharmaceuticals, Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
AMRX	Amneal Pharmaceuticals, Inc.	72%	Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers …
AZN	AstraZeneca PLC	72%	oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the …
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may …
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may …
BMY	Bristol-Myers Squibb Company	72%	oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the …
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency ma…
BMYMP	Bristol-Myers Squibb Co	72%	oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the …
FMS	Fresenius Medical Care AG	72%	Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
FMS	Fresenius Medical Care AG	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees …
GILD	Gilead Sciences, Inc.	72%	oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the …
MRK	Merck & Co., Inc.	72%	plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
REGN	Regeneron Pharmaceuticals, Inc.	72%	oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the …
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may…
BIOPHARMA-CREDIT-PLC	BIOPHARMA-CREDIT-PLC	62%	urchaser Group’s right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Revenue Payments once the Purchaser Group receives the amount equal to 2.25 times …
BPCR-LIMITED	BPCR-LIMITED	62%	costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. 98 Table of Contents On October 27, 2023, LOQTORZI was approved by the FDA in combination with ci…
CODUET-ROYALTY-HOLDINGS-LLC	CODUET-ROYALTY-HOLDINGS-LLC	62%	costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. 98 Table of Contents On October 27, 2023, LOQTORZI was approved by the FDA in combination with ci…
COMPANY-ANKURA-TRUST-COMPANY-LLC	COMPANY-ANKURA-TRUST-COMPANY-LLC	62%	duction in trade receivables. (2) This balance is expected to be settled in a front-weighted fashion over the remainder of 2026 and into 2027. 18 Table of Contents Cash flows from continuing operat…
COMPANY-LLC	COMPANY-LLC	62%	. On April 15, 2025, the Company paid $ 170.0 million in cash to repurchase $ 170.0 million aggregate principal amount of the 2026 Convertible Notes in privately negotiated transactions. On May 15, 2…
COMPUTERSHARE-TRUST-COMPANY	COMPUTERSHARE-TRUST-COMPANY	62%	with the development and commercialization of our product candidates and the extent to which we may enter into additional agreements with third parties to participate in their development and commerc…
CONDUET-ROYALTY-HOLDINGS-LLC	CONDUET-ROYALTY-HOLDINGS-LLC	62%	duction in trade receivables. (2) This balance is expected to be settled in a front-weighted fashion over the remainder of 2026 and into 2027. 18 Table of Contents Cash flows from continuing operat…
DEVELOPMENT-LLC	DEVELOPMENT-LLC	62%	duction in trade receivables. (2) This balance is expected to be settled in a front-weighted fashion over the remainder of 2026 and into 2027. 18 Table of Contents Cash flows from continuing operat…
HONG-KONG-KING-FRIEND-INDUSTRIAL-COMPANY-LTD	HONG-KONG-KING-FRIEND-INDUSTRIAL-COMPANY-LTD	62%	revenue was generated in the United States. The Company’s net revenue was as follows: Year Ended December 31, (in thousands) 2025 2024 LOQTORZI $ 40,836 $ …

Coherus Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CHRS-DEBT	Debt stack $73.7M	90%	Market cache reports total debt of $73.7M.
CHRS-DEBT-8637	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Coherus Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Coherus Oncology, Inc..

Coherus Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
CHRS-OWNER-BARCLAYS-PLC	BARCLAYS PLC	90%	13F overlay lists BARCLAYS PLC as top holder; 156 tracked holders.

Coherus Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ALLO	Allogene Therapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
CVS	CVS Health Corporation	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	1	['customer', 'supplier']
CABA	Cabaletta Bio, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
AMRX	Amneal Pharmaceuticals, Inc.	100.00	1	['customer', 'supplier']
CTMX	CytomX Therapeutics, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
DEO	Diageo plc	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer', 'supplier']
BEAM	Beam Therapeutics Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2

Coherus Oncology, Inc. Supply Chain